Literature DB >> 1446859

Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.

B Crotty1, W M Rosenberg, J K Aronson, D P Jewell.   

Abstract

5-Aminosalicylic acid (5ASA), 4ASA, their N-acetylated metabolites N-acetyl-5ASA and N-acetyl-4ASA, olsalazine, and colchicine impair interferon-gamma (IFN gamma) induced HLA-DR expression on a colonic cell line, HT-29. The mechanism of this effect is now reported. HT-29 cells were cultured with 50 U/ml IFN gamma with or without drug, and northern blot analysis was performed using a probe for the beta chain of the DR molecule. IFN gamma led to a noticeable increase in HLA-DR mRNA which was attenuated by the drugs. Analysis of the specific binding of increasing concentrations of 125I-IFN gamma by non-linear regression showed a Kd of 1.35 x 10(-10) M and 2.3 x 10(5) binding sites per HT-29 cell. Binding of 125I-IFN gamma was reduced by incubation with increasing concentrations of unlabelled IFN gamma but not with IFN alpha. Incubation with therapeutic concentrations of drugs led to the following reductions in binding: 10 mM 5ASA, 20% (p < 0.001); 10 mM N-acetyl-5ASA, 24% (p < 0.01); 10 mM 4ASA, 21% (p < 0.005); 10 mM N-acetyl-4ASA, 29% (p < 0.001); and 1 mM olsalazine, 29% (p < 0.001). Colchicine (10(-7) M) and 10(-5) M prednisolone had no effect. Incubation with higher concentrations of the drugs revealed a dose-response effect on binding with complete inhibition by 100 mM 4ASA and 10 mM olsalazine, and lesser degrees of inhibition by 100 mM 5ASA, N-acetyl-5ASA, and N-acetyl-4ASA. At concentrations found in the rectal lumen, the salicylates used in inflammatory bowel disease impair the binding of IFN gamma to its receptor on colonic epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446859      PMCID: PMC1379603          DOI: 10.1136/gut.33.10.1353

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  31 in total

Review 1.  Interleukins and the immune system 2.

Authors:  A O'Garra
Journal:  Lancet       Date:  1989-05-06       Impact factor: 79.321

2.  Relation between T cell number and epithelial HLA class II expression quantified by image analysis in normal and inflamed human gastric mucosa.

Authors:  K Valnes; H S Huitfeldt; P Brandtzaeg
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

Review 3.  Interferons.

Authors:  F R Balkwill
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

Review 4.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  M E Pickup
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

5.  Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon.

Authors:  G B McDonald; D P Jewell
Journal:  J Clin Pathol       Date:  1987-03       Impact factor: 3.411

6.  Up-regulation of the expression of secretory component and HLA molecules in a human colonic cell line by tumour necrosis factor-alpha and gamma interferon.

Authors:  D Kvale; P Brandtzaeg; D Løvhaug
Journal:  Scand J Immunol       Date:  1988-09       Impact factor: 3.487

7.  Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.

Authors:  R Eliakim; F Karmeli; E Razin; D Rachmilewitz
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

8.  HLA-DR-like antigens in the epithelium of the human small intestine.

Authors:  H Scott; B G Solheim; P Brandtzaeg; E Thorsby
Journal:  Scand J Immunol       Date:  1980       Impact factor: 3.487

9.  Inhibition of antibody secretion by 5-aminosalicylic acid.

Authors:  R P MacDermott; S R Schloemann; M J Bertovich; G S Nash; M Peters; W F Stenson
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

10.  Inhibition of prostaglandin synthetase in human rectal mucosa.

Authors:  C J Hawkey; M Lo Casto
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

View more
  10 in total

1.  Cytokine gene transcription of human colonic intraepithelial lymphocytes costimulated with epithelial cells bearing HLA-DR and its inhibition by 5-aminosalicylic acid.

Authors:  D Chen; G Radford-Smith; M C Dipaolo; I McGowan; D P Jewell
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

Review 2.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  Effect of gliadin and other food peptides on expression of MHC class II molecules by HT-29 cells.

Authors:  T Mothes; U Bendix; C Pfannschmidt; I Lehmann
Journal:  Gut       Date:  1995-04       Impact factor: 23.059

4.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

5.  5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon.

Authors:  M C Di Paolo; M N Merrett; B Crotty; D P Jewell
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

6.  Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease.

Authors:  G Goel; A J M Daveson; C E Hooi; J A Tye-Din; S Wang; E Szymczak; L J Williams; J L Dzuris; K M Neff; K E Truitt; R P Anderson
Journal:  Clin Exp Immunol       Date:  2019-10-01       Impact factor: 4.330

7.  5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats.

Authors:  Jyotirmoy Nandi; Bipin Saud; J Michael Zinkievich; David T Palma; Robert A Levine
Journal:  Dig Dis Sci       Date:  2007-05-15       Impact factor: 3.199

8.  Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.

Authors:  Glen A Doherty; Mark A Peppercorn
Journal:  Clin Exp Gastroenterol       Date:  2009-12-08

Review 9.  Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

10.  Loss of GRHL3 leads to TARC/CCL17-mediated keratinocyte proliferation in the epidermis.

Authors:  Stephen J Goldie; Denny L Cottle; Fiona H Tan; Suraya Roslan; Seema Srivastava; Rhys Brady; Darren D Partridge; Alana Auden; Ian M Smyth; Stephen M Jane; Sebastian Dworkin; Charbel Darido
Journal:  Cell Death Dis       Date:  2018-10-19       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.